ProfoundBio develops targeted therapeutics using proprietary antibody technologies to treat cancer and other serious diseases. Their approach focuses on creating differentiated antibody-based products that improve patient outcomes and address unmet medical needs in oncology.
Funding
$112M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ABFounders
Product
Problem
Many cancers lack effective treatments, and existing therapies often have significant side effects or limited efficacy due to a lack of specificity. This results in unmet medical needs and poor outcomes for patients with cancer and other serious diseases.
Solution
ProfoundBio is developing targeted antibody-based therapeutics designed to improve outcomes for patients with cancer and other serious diseases. They utilize proprietary antibody technologies to create differentiated products that address unmet needs in oncology. Their approach focuses on generating antibodies with enhanced specificity and efficacy, potentially minimizing off-target effects and improving patient outcomes.
Target Audience
The primary target audience includes patients with cancer and other serious diseases, as well as healthcare professionals seeking innovative treatment options.
Features
- Proprietary antibody discovery platforms for generating novel therapeutic candidates.
- Focus on developing targeted therapies with improved specificity for cancer cells.
- Pipeline of antibody-based products in clinical development for various oncology indications.